Tumor-associated carbohydrate antigens (TACAs) have been associated with cancer for decades1,2 and abnormal glycosylation is now accepted to be a universal feature of cancer.3 Despite the many roles glycosylation has been discovered to play in cancer progression and metastasis,4-6 progress in exploiting this knowledge in a clinical setting has been agonizingly slow.7-8 The epidermal growth factor receptor (EGFR) exemplifies the “sweet and sour”8 or “bittersweet”7 nature of glycosylation in cancer. This evidence concerns the gene EGFR and cancer.